Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Epilepsia ; 61(5): 914-923, 2020 05.
Article in English | MEDLINE | ID: mdl-32297665

ABSTRACT

OBJECTIVE: The antiepileptic drug candidate, padsevonil, is the first in a novel class of drugs designed to interact with both presynaptic and postsynaptic therapeutic targets: synaptic vesicle 2 proteins and γ-aminobutyric acid type A receptors (GABAA Rs), respectively. Functional aspects of padsevonil at the postsynaptic target, GABAA Rs, were characterized in experiments reported here. METHODS: The effect of padsevonil on GABA-mediated Cl- currents was determined by patch clamp on recombinant human GABAA Rs (α1ß2γ2) stably expressed in a CHO-K1 cell line and on native GABAA Rs in cultured rat primary cortical neurons. Padsevonil selectivity for GABAA R subtypes was evaluated using a two-electrode voltage clamp on recombinant human GABAA Rs (α1-5/ß2/γ2) in Xenopus oocytes. RESULTS: In recombinant GABAA Rs, padsevonil did not evoke Cl- currents in the absence of the agonist GABA. However, when co-administered with GABA at effective concentration (EC)20 , padsevonil potentiated GABA responses by 167% (EC50 138 nmol/L) and demonstrated a relative efficacy of 41% compared with zolpidem, a reference benzodiazepine site agonist. Similarly, padsevonil demonstrated GABA-potentiating activity at native GABAA Rs (EC50 208 nmol/L) in cultured rat cortical neurons. Padsevonil also potentiated GABA (EC20 ) responses in GABAA Rs expressed in oocytes, with higher potency at α1- and α5-containing receptors (EC50 295 and 281 nmol/L) than at α2- and α3-containing receptors (EC50 1737 and 2089 nmol/L). Compared with chlordiazepoxide-a nonselective, full GABAA R agonist-the relative efficacy of padsevonil was 60% for α1ß2γ2, 26% for α2ß2γ2, 56% for α3ß2γ2, and 41% for α5ß2γ2; no activity was observed at benzodiazepine-insensitive α4ß2γ2 receptors. SIGNIFICANCE: Results of functional investigations on recombinant and native neuronal GABAA Rs show that padsevonil acts as a positive allosteric modulator of these receptors, with a partial agonist profile at the benzodiazepine site. These properties may confer better tolerability and lower potential for tolerance development compared with classic benzodiazepines currently used in the clinic.


Subject(s)
Anticonvulsants/pharmacology , Imidazoles/pharmacology , Pyrrolidinones/pharmacology , Receptors, GABA-A/drug effects , Thiadiazoles/pharmacology , Animals , CHO Cells , Cricetulus , Female , Humans , Neurons/drug effects , Oocytes/drug effects , Oocytes/physiology , Patch-Clamp Techniques , Rats, Wistar , Receptors, Presynaptic/drug effects , Recombinant Proteins , Synaptic Potentials/drug effects , Xenopus laevis
2.
CNS Neurosci Ther ; 25(4): 442-451, 2019 04.
Article in English | MEDLINE | ID: mdl-30242974

ABSTRACT

AIMS: Kv1.1 (KCNA1) channels contribute to the control of neuronal excitability and have been associated with epilepsy. Kv1.1 channels can associate with the cytoplasmic Kvß1 subunit resulting in rapid inactivating A-type currents. We hypothesized that removal of channel inactivation, by modulating Kv1.1/Kvß1 interaction with a small molecule, would lead to decreased neuronal excitability and anticonvulsant activity. METHODS: We applied high-throughput screening to identify ligands able to modulate the Kv1.1-T1 domain/Kvß1 protein complex. We then selected a compound that was characterized on recombinant Kv1.1/Kvß1 channels by electrophysiology and further evaluated on sustained neuronal firing and on in vitro epileptiform activity using a high K+ -low Ca2+ model in hippocampal slices. RESULTS: We identified a novel compound able to modulate the interaction of the Kv1.1/Kvß1 complex and that produced a functional inhibition of Kv1.1/Kvß1 channel inactivation. We demonstrated that this compound reduced the sustained repetitive firing in hippocampal neurons and was able to abolish the development of in vitro epileptiform activity. CONCLUSIONS: This study describes a rational drug discovery approach for the identification of novel ligands that inhibit Kv1.1 channel inactivation and provides pharmacological evidence that such a mechanism translates into physiological effects by reducing in vitro epileptiform activity.


Subject(s)
Action Potentials/physiology , Drug Discovery/methods , Hippocampus/physiology , Kv1.1 Potassium Channel/physiology , Neurons/physiology , Action Potentials/drug effects , Animals , Dose-Response Relationship, Drug , Female , HEK293 Cells , High-Throughput Screening Assays/methods , Hippocampus/drug effects , Humans , Kv1.1 Potassium Channel/agonists , Kv1.1 Potassium Channel/antagonists & inhibitors , Neurons/drug effects , Organ Culture Techniques , Potassium Channel Blockers/pharmacology , Protein Structure, Secondary , Rats , Xenopus laevis
3.
Neuropharmacology ; 123: 322-331, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28533163

ABSTRACT

De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms. We investigated the effects of radiprodil, a selective GluN2B negative allosteric modulator and other non-selective NMDA receptor inhibitors on glutamate currents mediated by NMDA receptors containing mutated GluN2B subunits. The experiments were performed in Xenopus oocytes co-injected with the following human mRNAs: GRIN1/GRIN2B, GRIN1/GRIN2B-R540H, GRIN1/GRIN2B-N615I and GRIN1/GRIN2B-V618G. Glutamate displayed slightly increased potency in the R540H variant, but not in N615I and V618G variants. However, the inhibition by Mg2+ was completely abolished in N615I and V618G variants. In fact, Mg2+ enhanced glutamate responses in those variants. The potency of radiprodil to block glutamate-evoked currents was not affected in any of the variants, while the effects by non-selective NMDA inhibitors were greatly reduced in some of the variants. Additionally, in the Mg2+ insensitive variants, radiprodil blocked glutamate-activated currents with the same potency as in the absence of Mg2+. The gain of function observed in the reported GRIN2B variants could be a key pathophysiological factor leading to neuronal hyper-excitability in epileptic encephalopathies. The GluN2B-selective inhibitor radiprodil fully retained its pharmacological profile under these conditions, while other non-selective NMDA receptor antagonists lost their potency. Consequently, our data suggest that radiprodil may be a valuable therapeutic option for treatment of pediatric epileptic encephalopathies associated with GRIN2B mutations.


Subject(s)
Acetamides/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Gain of Function Mutation , Piperidines/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/genetics , Animals , Cations, Divalent/metabolism , Glutamic Acid/administration & dosage , Glutamic Acid/metabolism , Humans , Magnesium/metabolism , Models, Molecular , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Oocytes , Patch-Clamp Techniques , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Xenopus
4.
CNS Neurosci Ther ; 21(3): 241-51, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25444522

ABSTRACT

AIMS: Brivaracetam (BRV) is an antiepileptic drug in Phase III clinical development. BRV binds to synaptic vesicle 2A (SV2A) protein and is also suggested to inhibit voltage-gated sodium channels (VGSCs). To evaluate whether the effect of BRV on VGSCs represents a relevant mechanism participating in its antiepileptic properties, we explored the pharmacology of BRV on VGSCs in different cell systems and tested its efficacy at reducing the sustained repetitive firing (SRF). METHODS: Brivaracetam investigations on the voltage-gated sodium current (I(Na)) were performed in N1E-155 neuroblastoma cells, cultured rat cortical neurons, and adult mouse CA1 neurons. SRF was measured in cultured cortical neurons and in CA1 neurons. All BRV (100-300 µM) experiments were performed in comparison with 100 µM carbamazepine (CBZ). RESULTS: Brivaracetam and CBZ reduced IN a in N1E-115 cells (30% and 40%, respectively) and primary cortical neurons (21% and 47%, respectively) by modulating the fast-inactivated state of VGSCs. BRV, in contrast to CBZ, did not affect I(Na) in CA1 neurons and SRF in cortical and CA1 neurons. CBZ consistently inhibited neuronal SRF by 75-93%. CONCLUSIONS: The lack of effect of BRV on SRF in neurons suggests that the reported inhibition of BRV on VGSC currents does not contribute to its antiepileptic properties.


Subject(s)
Anticonvulsants/pharmacology , Membrane Potentials/drug effects , Neurons/drug effects , Voltage-Gated Sodium Channel Blockers/pharmacology , Animals , CA1 Region, Hippocampal/drug effects , CA1 Region, Hippocampal/physiology , Carbamazepine/pharmacology , Cell Line, Tumor , Cells, Cultured , Cerebral Cortex/drug effects , Cerebral Cortex/physiology , Clinical Trials, Phase III as Topic , Male , Membrane Potentials/physiology , Mice , Mice, Inbred C57BL , Neurons/physiology , Patch-Clamp Techniques , Rats, Wistar , Tissue Culture Techniques , Voltage-Gated Sodium Channels/metabolism
5.
J Biomol Screen ; 19(3): 462-7, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23989455

ABSTRACT

Gamma amino butyric acid receptors (GABA) are major therapeutic targets for the development of drugs in neurological and psychiatric disorders. The new generation of GABAA modulators is targeting subtype selectivity and low/partial efficacy on the receptor to potentially overcome the adverse effects described for drugs with full agonist profile. We evaluated a screening approach to measure the relative efficacy of GABAA positive allosteric modulators (PAM) using automated patch clamp and fluorescence membrane potential assays. We determined that the use of an internal comparator (zolpidem), tested on each cell in parallel to the test compound, provides a reliable approach to measure and compare the relative efficacy of PAM ligands. Patch clamp recordings on recombinant GABAA receptors, using a multiple drug addition protocol, allows us to rank PAM ligands with different levels of efficacies. We observed that fluorescence membrane potential assays are not predictive of the relative efficacies of GABAA PAM ligands.


Subject(s)
Drug Evaluation, Preclinical/methods , GABA-A Receptor Agonists/pharmacology , GABA-A Receptor Antagonists/pharmacology , Receptors, GABA-A/metabolism , Allosteric Regulation/drug effects , Animals , CHO Cells , Cell Line , Cricetulus , Drug Discovery , Humans , Patch-Clamp Techniques , Receptors, GABA-A/chemistry
6.
Biochem Pharmacol ; 75(2): 468-75, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-17920043

ABSTRACT

The present study was designed to further evaluate the biological effects and tissue selectivity of new 3-alkylaminobenzo- and 3-alkylaminopyridothiadiazine 1,1-dioxides bearing identical branched alkylamino chains at the 3-position. These original compounds were compared with their parent molecules; namely the K(ATP) channel openers diazoxide and pinacidil. All tested 3-alkylamino-substituted derivatives provoked a marked, concentration-dependent inhibition of the glucose-induced insulin secretion from rat pancreatic islets. The 3-alkylaminopyridothiadiazine 1,1-dioxides evoked a weak vasorelaxant activity whilst their 7-halo-substituted benzothiadiazine counterparts elicited pronounced, concentration-dependent, relaxations of rat aortic rings. The myorelaxant effect of the different drugs was tightly correlated with their capacity to increase (86)Rb outflow ((42)K substitute) from prelabelled and perifused rat aortic rings. EC(50)/IC(50) ratios (vascular/pancreatic) revealed a pronounced selectivity of the 3-alkylaminopyridothiadiazine 1,1-dioxides towards the pancreatic endocrine tissue. Structure-activity relationships suggest that, besides the requirement of an electronegative pole at the 7-position of the heterocycle, a minimal steric hindrance confers an optimal insulin-secreting cell selectivity. Lastly, radioisotopic, electrophysiological and pharmacological investigations indicate that the marked vasorelaxant properties of the 3-alkylaminobenzothiadiazine 1,1-dioxides are related to the activation of smooth muscle K(ATP) channels.


Subject(s)
KATP Channels/drug effects , Thiadiazines/pharmacology , Animals , Aorta/drug effects , Aorta/physiology , Glyburide/pharmacology , In Vitro Techniques , Insulin/metabolism , Insulin Secretion , Membrane Potentials/drug effects , Organ Specificity , Rats , Rats, Wistar , Structure-Activity Relationship , Vasoconstriction/drug effects
7.
Circulation ; 112(8): 1198-205, 2005 Aug 23.
Article in English | MEDLINE | ID: mdl-16116070

ABSTRACT

BACKGROUND: The therapeutic effects of nonspecific beta-blockers are limited by vasoconstriction, thus justifying the interest in molecules with ancillary vasodilating properties. Nebivolol is a selective beta1-adrenoreceptor antagonist that releases nitric oxide (NO) through incompletely characterized mechanisms. We identified endothelial beta3-adrenoreceptors in human coronary microarteries that mediate endothelium- and NO-dependent relaxation and hypothesized that nebivolol activates these beta3-adrenoreceptors. METHODS AND RESULTS: Nebivolol dose-dependently relaxed rodent coronary resistance microarteries studied by videomicroscopy (10 micromol/L, -86+/-6% of prostaglandin F2alpha contraction); this was sensitive to NO synthase (NOS) inhibition, unaffected by the beta(1-2)-blocker nadolol, and prevented by the beta(1-2-3)-blocker bupranolol (P<0.05; n=3 to 8). Importantly, nebivolol failed to relax microarteries from beta3-adrenoreceptor-deficient mice. Nebivolol (10 micromol/L) also relaxed human coronary microvessels (-71+/-5% of KCl contraction); this was dependent on a functional endothelium and NO synthase but insensitive to beta(1-2)-blockade (all P<0.05). In a mouse aortic ring assay of neoangiogenesis, nebivolol induced neocapillary tube formation in rings from wild-type but not beta3-adrenoreceptor- or endothelial NOS-deficient mice. In cultured endothelial cells, 10 micromol/L nebivolol increased NO release by 200% as measured by electron paramagnetic spin trapping, which was also reversed by NOS inhibition. In parallel, endothelial NOS was dephosphorylated on threonine(495), and fura-2 calcium fluorescence increased by 91.8+/-23.7%; this effect was unaffected by beta(1-2)-blockade but abrogated by beta(1-2-3)-blockade (all P<0.05). CONCLUSIONS: Nebivolol dilates human and rodent coronary resistance microarteries through an agonist effect on endothelial beta3-adrenoreceptors to release NO and promote neoangiogenesis. These properties may prove particularly beneficial for the treatment of ischemic and cardiac failure diseases through preservation of coronary reserve.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Benzopyrans/pharmacology , Coronary Circulation/drug effects , Ethanolamines/pharmacology , Nitric Oxide/metabolism , Receptors, Adrenergic, beta-3/metabolism , Vasodilation/drug effects , Animals , Calcium/metabolism , Coronary Circulation/physiology , Endothelium, Vascular/metabolism , Humans , Male , Mice , Microcirculation/drug effects , Microcirculation/physiology , Nebivolol , Nitrates/metabolism , Nitric Oxide Synthase Type III/metabolism , Nitrites/metabolism , Phosphorylation , Rats , Rats, Wistar , Vasodilation/physiology
8.
Eur J Pharmacol ; 517(1-2): 97-102, 2005 Jul 04.
Article in English | MEDLINE | ID: mdl-15958263

ABSTRACT

The diacylglycerol lipase inhibitor 1,6-bis(cyclohexyloximinocarbonylamino) hexane (RHC-80267) was tested for its effect on acetylcholine-evoked relaxation in rat mesenteric artery. In artery contracted with either noradrenaline or KCl, RHC-80267 (0.1-10 muM) potentiated the relaxation evoked by acetylcholine. The effect of RHC-80267 was not affected by nitric oxide synthase inhibition or by inhibitors of protein kinase C or of phospholipase A(2). The diacylglycerol analogue 1-oleoyl-2-acetyl-sn-glycerol did not change the relaxation to acetylcholine. RHC-80267 did not affect the relaxation evoked by carbachol, by the nitric oxide donor SNAP (S-nitroso-N-acetylpenicillamine) or by the K(+) channel opener cromakalim. Neostigmine, a cholinesterase inhibitor, produced the same effect as RHC-80267 on acetylcholine-evoked relaxation. When tested on cholinesterase in brain homogenate, RHC-80267 concentration-dependently inhibited cholinesterase activity with an IC(50) of 4 muM. These results indicate that the potentiation of acetylcholine-evoked responses by RHC-80267 in rat mesenteric artery is caused by the inhibition of the cholinesterase activity in the vascular wall.


Subject(s)
Acetylcholine/pharmacology , Cholinesterase Inhibitors/pharmacology , Cyclohexanones/pharmacology , Mesenteric Arteries/drug effects , Vasodilation/drug effects , Animals , Biological Factors/physiology , Cholinesterases/metabolism , Cromakalim/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , Endothelium, Vascular/physiology , Enzyme Inhibitors/pharmacology , In Vitro Techniques , Lipoprotein Lipase/antagonists & inhibitors , Male , Mesenteric Arteries/physiology , Naphthalenes/pharmacology , Neostigmine/pharmacology , Nitric Oxide/physiology , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitroarginine/pharmacology , Norepinephrine/pharmacology , Penicillamine/analogs & derivatives , Penicillamine/pharmacology , Phospholipases A/antagonists & inhibitors , Protein Kinase C/antagonists & inhibitors , Rats , Rats, Inbred WKY , Vasoconstrictor Agents/pharmacology , Vasodilator Agents/pharmacology
9.
Circ Res ; 95(2): 154-61, 2004 Jul 23.
Article in English | MEDLINE | ID: mdl-15205364

ABSTRACT

Nitric oxide (NO) is a powerful angiogenic mediator acting downstream of vascular endothelial growth factor (VEGF). Both the endothelial NO synthase (eNOS) and the VEGFR-2 receptor colocalize in caveolae. Because the structural protein of these signaling platforms, caveolin, also represses eNOS activity, changes in its abundance are likely to influence the angiogenic process in various ways. In this study, we used mice deficient for the caveolin-1 gene (Cav-/-) to examine the impact of caveolae suppression in a model of adaptive angiogenesis obtained after femoral artery resection. Evaluation of the ischemic tissue perfusion and histochemical analyses revealed that contrary to Cav+/+ mice, Cav-/- mice failed to recover a functional vasculature and actually lost part of the ligated limbs, thereby recapitulating the effects of the NOS inhibitor L-NAME administered to operated Cav+/+ mice. We also isolated endothelial cells (ECs) from Cav-/- aorta and showed that on VEGF stimulation, NO production and endothelial tube formation were dramatically abrogated when compared with Cav+/+ ECs. The Ser1177 eNOS phosphorylation and Thr495 dephosphorylation but also the ERK phosphorylation were similarly altered in VEGF-treated Cav-/- ECs. Interestingly, caveolin transfection in Cav-/- ECs redirected the VEGFR-2 in caveolar membranes and restored the VEGF-induced ERK and eNOS activation. However, when high levels of recombinant caveolin were reached, VEGF exposure failed to activate ERK and eNOS. These results emphasize the critical role of caveolae in ensuring the coupling between VEGFR-2 stimulation and downstream mediators of angiogenesis. This study also provides new insights to understand the paradoxical roles of caveolin (eg, repressing basal enzyme activity but facilitating activation on agonist stimulation) in cardiovascular pathophysiology.


Subject(s)
Caveolae/physiology , Caveolins/physiology , Neovascularization, Physiologic/physiology , Nitric Oxide/physiology , Vascular Endothelial Growth Factor A/pharmacology , Animals , Aorta , Caveolin 1 , Caveolins/deficiency , Caveolins/genetics , Cell Compartmentation , Cells, Cultured/metabolism , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Enzyme Activation , Extracellular Signal-Regulated MAP Kinases/physiology , Hindlimb/blood supply , Ischemia/physiopathology , Ischemia/therapy , Mice , Mice, Knockout , NG-Nitroarginine Methyl Ester/toxicity , Neovascularization, Physiologic/drug effects , Nitric Oxide Synthase/physiology , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Recombinant Fusion Proteins/physiology , Signal Transduction , Transfection , Vascular Endothelial Growth Factor Receptor-2/physiology
10.
J Neurochem ; 88(5): 1140-50, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15009669

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brain of senile plaques which contain an amyloid core made of beta-amyloid peptide (Abeta). Abeta is produced by the cleavage of the amyloid precursor protein (APP). Since impairment of neuronal calcium signalling has been causally implicated in ageing and AD, we have investigated the influence of an influx of extracellular calcium on the metabolism of human APP in rat cortical neurones. We report that a high cytosolic calcium concentration, induced by neuronal depolarization, inhibits the alpha-secretase cleavage of APP and triggers the accumulation of intraneuronal C-terminal fragments produced by the beta-cleavage of the protein (CTFbeta). Increase in cytosolic calcium concentration specifically induces the production of large amounts of intraneuronal Abeta1-42, which is inhibited by nimodipine, a specific antagonist of l-type calcium channels. Moreover, calcium release from endoplasmic reticulum is not sufficient to induce the production of intraneuronal Abeta, which requires influx of extracellular calcium mediated by the capacitative calcium entry mechanism. Therefore, a sustained high concentration of cytosolic calcium is needed to induce the production of intraneuronal Abeta1-42 from human APP. Our results show that this accumulation of intraneuronal Abeta1-42 induces neuronal death, which is prevented by a functional gamma-secretase inhibitor.


Subject(s)
Amyloid beta-Peptides/biosynthesis , Calcium/metabolism , Cytosol/metabolism , Neurons/metabolism , Peptide Fragments/biosynthesis , Adenoviridae/genetics , Amyloid Precursor Protein Secretases , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Aspartic Acid Endopeptidases , Calcium/pharmacology , Calcium Channel Blockers/pharmacology , Cell Death/drug effects , Cell Polarity/drug effects , Cell Survival/drug effects , Cells, Cultured , Endopeptidases/metabolism , Genetic Vectors/genetics , Humans , Neurons/drug effects , Nimodipine/pharmacology , Potassium Chloride/pharmacology , Rats , Rats, Wistar
11.
J Physiol ; 551(Pt 3): 855-67, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-12853654

ABSTRACT

The present study was aimed at investigating whether, besides its pivotal role in Ca(2+)-independent contraction of smooth muscle, Rho-kinase is involved in the mechanisms underlying the Ca2+ signal activated by noradrenaline in arteries. In rat aorta and mesenteric artery, the Rho-kinase inhibitor Y-27632 (10 microM) completely relaxed the contraction evoked by noradrenaline (1 microM) and simultaneously inhibited the Ca2+ signal by 54 +/- 1 % (mesenteric artery) and 71 +/- 15 % (aorta), and the cell membrane depolarisation by 56 +/- 11 % (mesenteric artery). A similar effect was observed in arteries contracted by AlF4-, while in KCl-contracted arteries, Y-27632 decreased tension without changing cytosolic Ca2+. The same effects were observed with another inhibitor of Rho-kinase (HA1077) but not with an inhibitor of protein kinase C (Ro-31-8220). Effects of Y-27632 were not prevented by incubating the artery in 25 mM KCl, with K+ channel blockers or with the Ca2+ channel blocker nimodipine. Y-27632 did not affect either the increase in the production of inositol phosphates activated by noradrenaline, or the release of Ca2+ from non-mitochondrial stores evoked by InsP3 in permeabilised aortic cells, or the Ca2+ signals evoked by thapsigargin or caffeine. The capacitative Ca2+ entry activated by thapsigargin was not impaired by Y-27632, but the entry of Ba2+ activated by noradrenaline in the presence of nimodipine was blocked by 10 microM Y-27632. These results indicate that Rho-kinase is involved in noradrenaline activation of a Ca2+ entry distinct from voltage- or store-operated channels in rat arteries.


Subject(s)
Calcium/metabolism , Muscle, Smooth, Vascular/enzymology , Protein Serine-Threonine Kinases/metabolism , Aluminum Compounds/pharmacology , Amides/pharmacology , Animals , Aorta/enzymology , Barium/pharmacokinetics , Calcium/pharmacology , Calcium Channel Blockers/pharmacology , Calcium Signaling/drug effects , Calcium Signaling/physiology , Enzyme Inhibitors/pharmacology , Fluorides/pharmacology , GTP-Binding Proteins/metabolism , Inositol Phosphates/biosynthesis , Intracellular Signaling Peptides and Proteins , Male , Mesenteric Arteries/enzymology , Mitochondria/metabolism , Muscle Contraction/drug effects , Muscle Contraction/physiology , Nimodipine/pharmacology , Norepinephrine/pharmacology , Potassium Channel Blockers/pharmacology , Potassium Chloride/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyridines/pharmacology , Rats , Rats, Wistar , Vasoconstrictor Agents/pharmacology , rho-Associated Kinases
SELECTION OF CITATIONS
SEARCH DETAIL
...